Conference Reports for NATAP

EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom  April 9-13 Back

Safety and Efficacy of Treatment With Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Patients With Genotypes 1-6 HCV Infection       Reported by Jules Levin EASL 2014 April 9-13 London, UK   Gregory T. Everson,1 Tram T. Tran,2 William J. Towner,3 Mitchell N. Davis,4 David Wyles,5 Ronald Nahass,6 John McNally,7 Diana M. Brainard,7 Lingling Han,7 Brian Doehle,7 Erik Mogalian,7 William T. Symonds,7 John G. McHutchison,7 Tim Morgan,8 Raymond T. Chung9 1University of Colorado Denver, Aurora, USA; 2Cedars-Sinai Medical Center, Los Angeles, CA, USA; 3Kaiser Permanente, Los Angeles, CA, USA; 4Digestive CARE, South Florida Center of Gastroenterology, LLC, Wellington, FL, USA; 5University of California, San Diego, CA, USA; 6ID CARE, Hillsborough, NJ, USA; 7Gilead Sciences, Inc., Foster City, CA, USA; 8VA Long Beach, Long Beach, CA; 9Massachusetts General Hospital, Boston, MA, USA